Gilteritinib recommended for relapsed or refractory acute myeloid leukaemia

The first oral monotherapy recommended for approval in the UK that targets relapsed or refractory FLT3 positive AML

Join OnMedica and benefit from:

  • Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
  • High-quality, evidence-based content developed by expert editors and clinicians
  • Articles, quizzes, videos, visual summaries and more
  • Regulatory alerts and round-up of medical journals
  • New content added daily, so you know you’re always up to date

Existing members Sign in